GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Net Income Including Noncontrolling Interests

RAPP (Rapport Therapeutics) Net Income Including Noncontrolling Interests : $-79.70 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Rapport Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was $-24.06 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was $-79.70 Mil.

Rapport Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Rapport Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics Net Income Including Noncontrolling Interests Chart

Rapport Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
- -34.79 -78.31

Rapport Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.67 -18.12 -17.54 -19.98 -24.06

Rapport Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-79.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Rapport Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapport Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
CELC TRML HUMA NWBO EYPT VERV TECX PGEN MBX SAGE VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
1325 Boylston Street, Suite 401, Boston, MA, USA, 02215
Website
https://www.rapportrx.com
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.